vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and SITIME Corp (SITM). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $113.3M, roughly 1.8× SITIME Corp). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 8.1%, a 49.3% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $13.0M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
IDYA vs SITM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $113.3M |
| Net Profit | $119.2M | $9.2M |
| Gross Margin | — | 56.4% |
| Operating Margin | 52.2% | 1.6% |
| Net Margin | 57.4% | 8.1% |
| Revenue YoY | — | 66.3% |
| Net Profit YoY | 330.1% | 148.7% |
| EPS (diluted) | $1.33 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $113.3M | ||
| Q3 25 | $207.8M | $83.6M | ||
| Q2 25 | — | $69.5M | ||
| Q1 25 | — | $60.3M | ||
| Q4 24 | — | $68.1M | ||
| Q3 24 | $0 | $57.7M | ||
| Q2 24 | $0 | $43.9M | ||
| Q1 24 | $0 | $33.0M |
| Q4 25 | — | $9.2M | ||
| Q3 25 | $119.2M | $-8.0M | ||
| Q2 25 | — | $-20.2M | ||
| Q1 25 | — | $-23.9M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $-51.8M | $-19.3M | ||
| Q2 24 | $-52.8M | $-26.8M | ||
| Q1 24 | $-39.6M | $-28.7M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 51.9% | ||
| Q1 25 | — | 50.3% | ||
| Q4 24 | — | 52.6% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.1% | ||
| Q1 24 | — | 53.5% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 52.2% | -19.2% | ||
| Q2 25 | — | -35.4% | ||
| Q1 25 | — | -46.6% | ||
| Q4 24 | — | -33.8% | ||
| Q3 24 | — | -43.1% | ||
| Q2 24 | — | -73.7% | ||
| Q1 24 | — | -106.1% |
| Q4 25 | — | 8.1% | ||
| Q3 25 | 57.4% | -9.6% | ||
| Q2 25 | — | -29.0% | ||
| Q1 25 | — | -39.6% | ||
| Q4 24 | — | -27.6% | ||
| Q3 24 | — | -33.5% | ||
| Q2 24 | — | -61.0% | ||
| Q1 24 | — | -86.9% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | $1.33 | $-0.31 | ||
| Q2 25 | — | $-0.84 | ||
| Q1 25 | — | $-1.01 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-0.60 | $-0.83 | ||
| Q2 24 | $-0.68 | $-1.16 | ||
| Q1 24 | $-0.53 | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $1.2B |
| Total Assets | $1.2B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $786.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $692.5M | ||
| Q4 24 | — | $699.7M | ||
| Q3 24 | $1.2B | $696.2M | ||
| Q2 24 | $931.7M | $692.5M | ||
| Q1 24 | $935.3M | $696.2M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $872.1M | ||
| Q4 24 | — | $885.0M | ||
| Q3 24 | $1.2B | $877.9M | ||
| Q2 24 | $973.7M | $878.6M | ||
| Q1 24 | $961.5M | $942.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $25.4M |
| Free Cash FlowOCF − Capex | $142.2M | $13.0M |
| FCF MarginFCF / Revenue | 68.4% | 11.5% |
| Capex IntensityCapex / Revenue | 0.0% | 10.9% |
| Cash ConversionOCF / Net Profit | 1.19× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $25.4M | ||
| Q3 25 | $142.2M | $31.4M | ||
| Q2 25 | — | $15.3M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $-49.2M | $8.2M | ||
| Q2 24 | $-32.9M | $-181.0K | ||
| Q1 24 | $-43.8M | $1.7M |
| Q4 25 | — | $13.0M | ||
| Q3 25 | $142.2M | $26.3M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $-2.4M | ||
| Q3 24 | $-49.7M | $-6.7M | ||
| Q2 24 | $-33.9M | $-2.7M | ||
| Q1 24 | $-45.1M | $-1.2M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | 68.4% | 31.5% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -2.1% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | -11.6% | ||
| Q2 24 | — | -6.3% | ||
| Q1 24 | — | -3.6% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | 0.0% | 6.1% | ||
| Q2 25 | — | 26.2% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 23.3% | ||
| Q3 24 | — | 25.7% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
